Sophiris Bio Inc. (NASDAQ:SPHS) shares dropped 3.4% during mid-day trading on Thursday . The company traded as low as $2.55 and last traded at $2.59, with a volume of 760,134 shares changing hands. The stock had previously closed at $2.68.

SPHS has been the subject of a number of research analyst reports. Echelon Wealth Partners reissued a “buy” rating and issued a $5.00 target price on shares of Sophiris Bio in a research note on Friday, June 10th. Maxim Group reissued a “buy” rating and issued a $4.00 target price on shares of Sophiris Bio in a research note on Friday, June 10th.

The firm’s market capitalization is $55.37 million. The stock’s 50-day moving average price is $1.87 and its 200-day moving average price is $1.64.

Sophiris Bio (NASDAQ:SPHS) last announced its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.06. Equities analysts predict that Sophiris Bio Inc. will post ($0.73) EPS for the current year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.